BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder. The company said it is exploring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback